United States Patent 7,115,564 scope and claims: stabilized dalbavancin dry dosage form (mannitol/lactose, pH 3–5)
United States Patent 7,115,564 protects a narrowly defined lyophilized or otherwise “dry” dalbavancin reconstitution product with (i) a specific stabilization system (mannitol plus lactose) and (ii) an acidic final pH window (about 3 to about 5; with dependent claims tightening to about 3.5 to about 4.5 and even about 4.5). Independent claim 1 is anchored to the presence of both stabilizers and the pH range in the dry dosage form (as characterized in the claim), which constrains design-around strategies that remove one excipient, change the pH outside the window, or reformulate with alternative stabilizers.
What exactly do the asserted claims cover?
The claim set provided defines the invention as a stabilized dry reconstitution dosage form of dalbavancin with:
- Active: dalbavancin
- Stabilizers: mannitol and lactose (both present)
- pH: about 3 to about 5
Dependent claims further restrict:
- Claim 2: weight ratio mannitol:lactose:dalbavancin of about 1:1:4
- Claim 3: pH about 3.5 to about 4.5
- Claim 4: pH about 4.5
Practical claim boundaries (high-level)
- “Dry dosage form for reconstitution” captures solid formulations intended to be reconstituted prior to administration (commonly lyophilized powders, but the claim language as given does not limit to lyophilization unless the patent specification does).
- “Effective stabilizer comprising mannitol and lactose” requires mannitol and lactose to be part of the stabilizer system; it does not, based on the claim text alone, forbid additional excipients if they do not remove mannitol and lactose from the stabilizer “comprising” language.
- The pH constraint is a key infringement gate. A product that is outside the claimed pH range as characterized for the dosage form avoids the claims if pH is measured in the same way the patent defines.
What is the claim 1 scope for US 7,115,564 (mannitol + lactose, dalbavancin, pH 3–5)?
Claim 1 is the core independent protection and reads, on its face, as a two-element invention:
- composition: dalbavancin with a stabilizer system comprising mannitol and lactose
- process/characteristic: the pH of the dry dosage form is about 3 to about 5
How broad is “comprising” for the stabilizer?
“Comprising” typically allows additional components. As written, it requires that the stabilizer system includes mannitol and lactose, not that these are the only stabilizers. That means a formulation can still infringe even if it contains other excipients (buffers, bulking agents, cryoprotectants, tonicity agents, etc.), provided mannitol and lactose remain part of the stabilizer system and the pH requirement is met.
How broad is the pH “about 3 to about 5”?
The phrase “about” expands tolerance beyond exact numerical values. Claim 3 and claim 4 add narrower targets, which signals that the patentee sought to cover a band of acidic pH and then highlight specific subranges as especially important. From an infringement-risk perspective, products that land near the edges (for example, 3.0, 5.0, or the high-4s region) stay within potential “about” interpretations.
Infringement leverage point
Claim 1 is easier to risk with if a generic or follow-on formulation:
- uses dalbavancin
- includes mannitol and lactose as stabilizers
- and targets an acidic pH in the claimed window
What do dependent claims 2–4 narrow beyond claim 1?
Claim 1 covers the general stabilized dry dalbavancin formulation at pH 3–5 with mannitol + lactose. Claims 2–4 narrow to specific quantification and pH subranges.
Claim 2: fixed weight ratio mannitol:lactose:dalbavancin = about 1:1:4
This dependent claim adds a stoichiometric constraint. Even if a product meets the general stabilizer and pH windows, it may avoid claim 2 if its ratio differs materially outside “about.”
Key implication: a competitor can aim for:
- pH within claim 1 but different ratio to reduce claim 2 exposure
- but still remain exposed under claim 1 if it keeps mannitol + lactose and the pH window
Claim 3: pH about 3.5 to about 4.5
Claim 3 carves out a narrower acidic range. Any competitor staying below 3.5 or above 4.5 may reduce claim 3 risk, but still may infringe claim 1 if the overall pH remains between 3 and 5.
Claim 4: pH about 4.5
This is the most specific pH point. A product engineered to avoid being “about 4.5” could still fall into claim 1 if it remains between 3 and 5, and could still risk claim 3 if it lands between 3.5 and 4.5.
What formulation design-arounds address US 7,115,564 risk fastest?
Based on the claim language alone, the most direct design-arounds fall into three buckets: excipient set, pH, or both.
1) Remove one required stabilizer: omit mannitol or lactose
Because claim 1 requires stabilizer “comprising mannitol and lactose,” removing either mannitol or lactose from the stabilizer system is the cleanest avoidance path on paper. If “comprising” allows the presence of both, it does not help if one is missing.
2) Keep both excipients but move pH outside 3–5
Claim 1 requires pH about 3 to about 5. Shifting to pH <3 or pH >5 can avoid claim 1, and by extension likely avoids all dependent claims, since they sit within or near that base window.
3) Keep excipients and pH but change ratios (target claim 2 avoidance)
Changing the mannitol:lactose:dalbavancin ratio can reduce exposure under claim 2. This does not remove exposure under claim 1 unless ratio changes also force pH changes or changes to stabilizer presence.
How does the patent landscape likely look around this formulation?
A patent like US 7,115,564 is typically one node within a larger formulation and process estate around dalbavancin dry products and reconstitution stability. Even without the full file history and additional claim sets, the claim scope suggests a formulation strategy: acidic pH plus a mannitol/lactose stabilizer system.
In US practice, competing products frequently test:
- alternative solid-state forms
- alternative stabilizer systems (different sugar alcohols, different sugars, different buffering systems)
- different reconstitution pH targets
- different excipient ratios
That means the “closest” freedom-to-operate questions usually cluster around other US patents that cover:
- solid-state dalbavancin formulations
- different stabilizer combinations (including but not limited to mannitol and lactose)
- specific pH targets and reconstitution conditions
- lyophilization/cake appearance and residual moisture requirements
- method-of-making or method-of-reconstitution claims
What is the litigation risk profile for formulations like this?
For a formulation patent driven by composition and pH:
- A Paragraph IV challenger must present a credible non-infringement or invalidity case. Non-infringement arguments usually center on missing excipients (omitting mannitol or lactose) and pH measurement/target differences.
- Validity challenges often attack predictability (whether acidic pH and these stabilizers were already taught for dalbavancin or similar antibiotics) and definiteness (how “pH of the dosage form” is measured and supported).
- If there are multiple related patents (continuations, divisionals, or separate patents on pH vs excipient system), a competitor can face claim stacking, where avoiding claim 1 simply moves infringement to a neighboring formulation patent.
Key claim-to-design mapping (fast infringement screening)
| Design choice |
Effect on claim 1 |
Effect on claim 2 |
Effect on claim 3 |
Effect on claim 4 |
| Include dalbavancin + mannitol + lactose, pH within 3–5 |
Likely in-scope |
Depends on ratio |
Likely if pH within 3.5–4.5 |
Likely if pH about 4.5 |
| Omit mannitol |
Avoids claim 1 (stabilizer must include both) |
Avoids |
Avoids |
Avoids |
| Omit lactose |
Avoids claim 1 |
Avoids |
Avoids |
Avoids |
| Keep both, but pH <3 |
Avoid claim 1 |
Avoid |
Avoid |
Avoid |
| Keep both, but pH >5 |
Avoid claim 1 |
Avoid |
Avoid |
Avoid |
| Keep both and pH within 3–5, change ratio |
In-scope for claim 1 |
May avoid claim 2 |
Depends on pH |
Depends on pH |
| Keep both and pH within 3.5–4.5 |
In-scope for claim 1 |
Depends |
In-scope |
Risk if near 4.5 |
What additional patent-claim “angles” usually accompany this type of claim?
Even though only claims 1–4 are provided, the claim structure points to common adjacent IP themes that could exist in the same patent family or related patents:
- Measurement and definition of pH “of the dosage form” (pH of a reconstituted solution versus pH as prepared in the solid state, or pH after reconstitution).
- Specificity of the stabilizer: whether lactose is described as reducing or non-reducing, and whether lactose is present as monohydrate or other grade.
- Solid-state stability: residual moisture and reconstitution behavior, where acidic pH is used to control degradation pathways.
- Lyophilization parameters or solids fraction, if “dry dosage form” is tied to a manufacturing method in the specification.
Patent strength and claim enforceability signals from the provided language
- Strength: The independent claim is clear on required elements: dalbavancin, mannitol + lactose, and acidic pH range.
- Enforceability: “about” ranges and “comprising” language suggest tolerance and broader inclusion, which reduces a competitor’s ability to avoid purely by small formulation changes.
- Weakness points competitors can exploit (depending on record): The narrowing dependent pH claims indicate the criticality of the pH window. If a competitor demonstrates a pH outside the band using the patent’s measurement approach, it can defeat claim 1 outright.
- Key evidence likely needed in enforcement: formulation examples in the specification, analytical methods used to define pH, and stability data showing the stabilizer system works at those pH levels.
Key Takeaways
- US 7,115,564 claim 1 requires dalbavancin in a stabilized dry reconstitution dosage form with a stabilizer system comprising both mannitol and lactose and a pH about 3 to about 5.
- Dependent claim 2 further restricts the mannitol:lactose:dalbavancin weight ratio to about 1:1:4.
- Dependent claims 3–4 narrow pH to about 3.5–4.5 and about 4.5, respectively.
- Fastest paper design-arounds are removing mannitol or lactose and/or moving the pH outside 3–5; changing ratios alone mainly reduces exposure under claim 2, not claim 1.
FAQs
1) What constitutes “pH of the dosage form” for US 7,115,564?
The claim ties pH to the dry dosage form; infringement depends on how pH is measured in line with the patent’s definitions and the product’s analytical characterization.
2) Can a formulation with additional excipients still infringe if it has mannitol, lactose, and pH 3–5?
Yes in principle, because the stabilizer is “comprising,” so additional components do not avoid infringement if mannitol and lactose remain part of the stabilizer system and the pH condition is met.
3) Does changing the mannitol-to-lactose-to-dalbavancin ratio avoid the patent?
It can avoid claim 2 if materially outside the about 1:1:4 range, but it does not avoid claim 1 unless the pH or excipient inclusion is also changed.
4) How do I reduce risk specifically for the pH 4.5 dependent claim?
A formulation should target a pH that is not “about 4.5.” If it stays within 3–5, claim 1 and possibly claim 3 can still apply.
5) What is the main risk factor in moving from an acidic to a neutral formulation?
Moving pH outside the claimed 3–5 window is the primary lever to exit claim 1 coverage; if pH remains within 3–5, excipient changes must address mannitol and/or lactose to reduce core infringement risk.
References
- US Patent 7,115,564 (claims 1–4 as provided by user).
